open access

Vol 50, No 3 (2012)
ORIGINAL PAPERS
Published online: 2012-10-08
Submitted: 2012-10-08
Accepted: 2012-10-08
Get Citation

Complement inhibitory proteins expression in placentas of thrombophilic women

Przemysław Krzysztof Wirstlein, Piotr Jasiński, Marcin Rajewski, Tomasz Goździewicz, Jana Skrzypczak
DOI: 10.5603/FHC.2012.0064
·
Folia Histochem Cytobiol 2012;50(3):460-467.

open access

Vol 50, No 3 (2012)
ORIGINAL PAPERS
Published online: 2012-10-08
Submitted: 2012-10-08
Accepted: 2012-10-08

Abstract

Factors controlling complement activation appear to exert a protective effect on pregnancy. This is
particularly important in women with thrombophilia. The aim of this study was to determine the transcript and
protein levels of complement decay-accelerating factor (DAF) and membrane cofactor protein (MCP) in the
placentas of women with acquired and inherited thrombophilia. Also, we assessed immunohistochemistry staining
of inhibitors of the complement cascade, DAF and MCP proteins, in the placentas of thrombophilic women.
Placentas were collected from eight women with inherited thrombophilia and ten with acquired thrombophilia.
The levels of DAF and MCP transcripts were evaluated by qPCR, the protein level was evaluated by Western
blot. We observed a higher transcript (p < 0.05) and protein (p < 0.001) levels of DAF and MCP in the placentas
of thrombophilic women than in the control group. DAF and MCP were localized on villous syncytiotrophoblast
membranes, but the assessment of staining in all groups did not differ. The observed higher expression level of
proteins that control activation of complement control proteins is only seemingly contradictory to the changes
observed for example in the antiphospholipid syndrome. However, given the hitherto known biochemical changes
associated with thrombophilia, a mechanism in which increased expression of DAF and MCP in the placentas is
an effect of proinflammatory cytokines, which accompanies thrombophilia, is probable.

Abstract

Factors controlling complement activation appear to exert a protective effect on pregnancy. This is
particularly important in women with thrombophilia. The aim of this study was to determine the transcript and
protein levels of complement decay-accelerating factor (DAF) and membrane cofactor protein (MCP) in the
placentas of women with acquired and inherited thrombophilia. Also, we assessed immunohistochemistry staining
of inhibitors of the complement cascade, DAF and MCP proteins, in the placentas of thrombophilic women.
Placentas were collected from eight women with inherited thrombophilia and ten with acquired thrombophilia.
The levels of DAF and MCP transcripts were evaluated by qPCR, the protein level was evaluated by Western
blot. We observed a higher transcript (p < 0.05) and protein (p < 0.001) levels of DAF and MCP in the placentas
of thrombophilic women than in the control group. DAF and MCP were localized on villous syncytiotrophoblast
membranes, but the assessment of staining in all groups did not differ. The observed higher expression level of
proteins that control activation of complement control proteins is only seemingly contradictory to the changes
observed for example in the antiphospholipid syndrome. However, given the hitherto known biochemical changes
associated with thrombophilia, a mechanism in which increased expression of DAF and MCP in the placentas is
an effect of proinflammatory cytokines, which accompanies thrombophilia, is probable.
Get Citation
About this article
Title

Complement inhibitory proteins expression in placentas of thrombophilic women

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 50, No 3 (2012)

Pages

460-467

Published online

2012-10-08

DOI

10.5603/FHC.2012.0064

Bibliographic record

Folia Histochem Cytobiol 2012;50(3):460-467.

Authors

Przemysław Krzysztof Wirstlein
Piotr Jasiński
Marcin Rajewski
Tomasz Goździewicz
Jana Skrzypczak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl